Allison Berger

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Teresa A. Soucy, Peter G. Smith, Michael A. Milhollen et al. · Nature · 2009 · 2K citations

Medicine, Medicinal Chemistry, Oncology +8

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

Erik Kupperman, Edmund C. Lee, Yueying Cao et al. · Cancer Research · 2010 · 493 citations

Medicine, Oncology, Pharmacology +13

MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma

Michael A. Milhollen, Tary Traore, Jennifer Adams-Duffy et al. · Blood · 2010 · 323 citations · Full text

Medicine, Molecular Biology, Oncology +11

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

Jatin J. Shah, Andrzej Jakubowiak, Owen A. O’Connor et al. · Clinical Cancer Research · 2015 · 190 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors

John Sarantopoulos, Geoffrey I. Shapiro, Roger B. Cohen et al. · Clinical Cancer Research · 2015 · 165 citations

Medicine, Oncology, Pharmacology +17